To verify whether IGFBP3 could act as a key target in SLE, based on high-throughput analysis, six datasets were selected as verification sets to screen significantly differentially expressed m6A regulators after the ChIP results were normalized. The gene discussed is IGFBP3; the disease is systemic lupus erythematosus.